Project Grant R35GM153349
- This collaborative research project, funded by the National Science Foundation's Division of Molecular and Cellular Biosciences under the Biological Sciences program (CFDA 47.074), investigates the synthesis and enzymatic mechanisms of ceramide phosphoglycerate (CPG2) in gram-negative bacteria. The $481,722 award to Stony Brook University, spanning September 1, 2025, through August 31, 2028, focuses on understanding how bacteria can survive without lipopolysaccharide (LPS) by producing CPG2 as...
- FEDERAL PROJECT GRANT AWARD SUMMARY Emory University received a $430,375 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 1, 2025, with a completion date of July 31, 2027. The research project, titled "Inter-Membrane Lipid Signaling for Preserving Gram-Negative Outer Membrane Integrity and Antibiotic Resistance," will be conducted at Emory's Atlanta,...
- Project Grant Summary This collaborative research project, funded by the National Science Foundation's Division of Molecular and Cellular Biosciences under the Biological Sciences program (CFDA 47.074), received an award of $791,029 effective September 1, 2025, through August 31, 2028. The project is being conducted at Rutgers, The State University of New Jersey, Camden Division and focuses on elucidating the synthesis and enzymatic mechanisms of ceramide phosphoglycerate (CPG2), a lipid that...
- This Project Grant award for $382,616.00, funded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), supports research to elucidate the structure, function, and mechanism of bacterial ATP-binding cassette (ABC) transporters that regulate the essential metal zinc. The research aims to determine high-resolution structures of two divergent zinc ABC transporter systems, ZnuABC and ZrgABCDE, which are prevalent in...
- Federal Grant Award Summary The University of Georgia Research Foundation, Inc. received a $394,068 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), awarded on June 1, 2025, with a completion date of April 30, 2030. This award supports fundamental research investigating the molecular mechanisms of lipid transporters from the Major Facilitator Superfamily (MFS) and the Multidrug...
- Federal Grant Award Summary Oregon State University received a $399,081 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective September 1, 2025 through August 31, 2030. This five-year research initiative focuses on elucidating the molecular mechanisms of lipid transfer by bridge-like lipid transfer proteins (BLTPs), which are essential for fundamental cellular processes including cell...
- This three-year Project Grant from the National Science Foundation's Division of Molecular and Cellular Biosciences totals $1,512,792 to fund research at Louisiana State University examining the gene regulatory networks affected by purine catabolites in bacterial pathogens. The research aims to identify additional transcription factors in Burkholderia thailandensis responsive to urate and xanthine, which accumulate in host tissues during infection due to production of reactive oxygen species....
- The National Science Foundation (NSF) Division of Molecular and Cellular Biosciences awarded a $1,000,000 Project Grant under the Biological Sciences program (CFDA 47.074) to the University of Wisconsin-Madison. The 3-year grant, effective September 1, 2023, supports a collaborative research project between the University of Wisconsin-Madison and members of the Department of Energy's Agile Biofoundry to investigate bacterial transporters and engineer them for superior properties in...
- This Project Grant award from the National Science Foundation (NSF) under the Biological Sciences (CFDA 47.074) program provides $1,035,238 to the University of Utah to study the mechanisms by which Pseudomonas plant pathogens use specialized molecular "killing machines" called tailocins to target and eliminate competing bacteria without harming their own strain. The research aims to elucidate how differences in the lipopolysaccharide composition of bacterial cell membranes confer...
- This federal Project Grant award, provided by the National Science Foundation (NSF) through its Biological Sciences program (CFDA 47.074), supports fundamental research on the periplasmic chaperone network in bacterial cell surface formation. The $1,320,970 award to The Johns Hopkins University will investigate the physical principles and mechanisms governing this essential cellular process in bacteria, one of the most abundant forms of life on Earth. The multi-scale research approach will...
ENVELOPE BIOGENESIS IN GRAM-NEGATIVE BACTERIA - PROJECT SUMMARY BACTERIA INTERACT WITH THE OUTSIDE WORLD THROUGH THEIR CELL ENVELOPE. THE CELL ENVELOPE DEFINES CELL BOUNDARIES AND PROVIDES STRUCTURAL INTEGRITY AND CELL SHAPE TO BACTERIA. THEREFORE, PROPERLY BUILDING THEIR MULTI-STRUCTURE ENVELOPE IS CRITICAL TO ENSURE GROWTH AND SURVIVAL. IN GRAM-NEGATIVE BACTERIA, THE CELL ENVELOPE IS DELIMITED BY TWO LIPID BILAYERS, THE INNER MEMBRANE AND THE OUTER MEMBRANE. THESE MEMBRANES ARE SEPARATED BY AN AQUEOUS COMPARTMENT KNOWN AS THE PERIPLASM, WHICH ALSO CONTAINS A THIN PEPTIDOGLYCAN CELL WALL. THE STRUCTURE AND COMPOSITION OF THE GRAM-NEGATIVE OUTER MEMBRANE IS UNUSUAL MAINLY BECAUSE IT IS NOT A PHOSPHOLIPID BILAYER. ITS INNER LEAFLET CONTAINS GLYCEROPHOSPHOLIPIDS, BUT ITS OUTER LEAFLET IS COMPOSED OF LIPOPOLYSACCHARIDES (LPS). BY DENSELY PACKING THEIR CELL SURFACE WITH LPS MOLECULES, GRAM-NEGATIVE BACTERIA CREATE A PERMEABILITY BARRIER AGAINST SMALL HYDROPHOBIC MOLECULES THAT OTHERWISE COULD DIFFUSE ACROSS PHOSPHOLIPID BILAYERS. CONSEQUENTLY, THESE BACTERIA ARE NATURALLY RESISTANT TO MANY ANTIBIOTICS AND DETERGENTS. THE LONG-TERM PLAN OF OUR RESEARCH PROGRAM IS TO INVESTIGATE HOW GRAM-NEGATIVE BACTERIA BUILD THEIR CELL ENVELOPE. THIS PROJECT FOCUSES ON UNDERSTANDING OUTER MEMBRANE BIOGENESIS BY STUDYING THE MECHANISM OF FUNCTION OF LIPID TRANSPORTERS THAT BUILD THIS BILAYER. OUTER-MEMBRANE LIPIDS ARE SYNTHESIZED IN THE INNER MEMBRANE, SO THEY MUST TRAVEL THROUGH THE AQUEOUS PERIPLASMIC COMPARTMENT AND BE ASYMMETRICALLY DELIVERED TO THE OUTER MEMBRANE. THE PROPOSED RESEARCH PLAN WILL LEVERAGE OUR EXPERTISE IN APPLYING GENETIC AND BIOCHEMICAL APPROACHES TO STUDY THE CELL ENVELOPE IN ORDER TO INVESTIGATE TWO HIGHLY CONSERVED SYSTEMS THAT ARE ESSENTIAL FOR OUTER-MEMBRANE BIOGENESIS AND GROWTH OF THE GRAM-NEGATIVE BACTERIUM ESCHERICHIA COLI. WE WILL INVESTIGATE HOW THE LPT SYSTEM EXTRACTS NEWLY SYNTHESIZED LPS MOLECULES FROM THE INNER MEMBRANE AND TRANSPORTS THEM ACROSS THE CELL ENVELOPE THROUGH A PROTEIN BRIDGE SO THAT THEY CAN BE ASSEMBLED AT THE CELL SURFACE. OUR STUDIES WILL FOCUS ON HOW LPS EXTRACTION AND TRANSPORT ARE POWERED BY THE LPTB2FGC COMPONENTS, WHICH CONSTITUTE AN ATP-BINDING CASSETTE (ABC) TRANSPORTER AT THE INNER MEMBRANE. ABC TRANSPORTERS ARE ATP-DRIVEN MACHINES THAT ALL CELLS USE TO MOVE SUBSTRATES ACROSS CELLULAR COMPARTMENTS. WE WILL ALSO INVESTIGATE TRANSPORT OF PHOSPHOLIPIDS FROM THE INNER TO THE OUTER MEMBRANE BY NEWLY DISCOVERED BRIDGE-LIKE PROTEINS BELONGING TO THE ASMA-LIKE PROTEIN FAMILY. THESE PROTEINS HAVE RECENTLY BEEN RECOGNIZED AS THE BACTERIAL ANCESTORS OF LIPID-TRANSFER PROTEINS THAT TRANSPORT PHOSPHOLIPIDS AT CONTACT SITES BETWEEN MEMBRANES OF DIFFERENT ORGANELLES IN EUKARYOTIC CELLS. OUR RESEARCH WILL THEREFORE PROVIDE FUNDAMENTAL KNOWLEDGE ABOUT BACTERIAL PHYSIOLOGY AND GROWTH THAT IS ALSO APPLICABLE TO HOMOLOGOUS SYSTEMS CONSERVED ACROSS MANY ORGANISMS. IN ADDITION, SINCE THE BARRIER IMPOSED BY THE OUTER MEMBRANE IS THE MAIN REASON WHY VERY FEW NOVEL ANTIBIOTICS EFFECTIVE AGAINST GRAM-NEGATIVE PATHOGENS HAVE BEEN DEVELOPED IN DECADES, THE KNOWLEDGE OBTAINED FROM OUR RESEARCH WILL CONTRIBUTE TO THE DEVELOPMENT OF NOVEL ANTIMICROBIALS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $379.4k | 4/29/25 | ||
| Not listed | $0 | 11/5/24 | ||
| Not listed | $0 | 11/5/24 | ||
| Not listed | $297.3k | 5/13/24 | ||
| Not listed | $297.3k | 5/13/24 |